The Global CAR-T Map: Seventeen Approved Products, Nine of Them Chinese

A patient in Jakarta, a patient in Lagos and a patient in Almaty are asked the same question by their families in three different languages, and it amounts to the same thing: where in the world can I actually get this treatment. Five years ago the honest answer was one country, and the barrier was money and a visa in roughly equal measure. That answer has stopped being true, and the reason is not that the therapy got better. It is that the approval map got wider.

Seventeen CAR-T products now hold national marketing approval somewhere in the world. Nine of them are Chinese. But the totals are where most reporting stops, and the totals are the least useful part of the story, for a reason that will become clear: a product approved in Seoul is not available in Shenzhen, a product approved in Shanghai is not licensed in Manila, and the number that decides a patient's options is the number approved in the country that will treat them.

This piece works through the map in the order a planning conversation would: what has actually been approved and where, how the acquisition wave has been reshaping who can bring what to which country, which technical bets are still open, and — at the end — four questions worth asking of any claim built on these numbers.

Seventeen, Eighteen, or Nineteen: Why the Count Disagrees

The discrepancy is not sloppiness. It comes from a genuine difference in what is being counted, and it is worth thirty seconds because the same confusion distorts every comparison a patient will read.

Seventeen counts products that hold a national marketing authorisation — an approval from the FDA, the NMPA, India's CDSCO, Korea's MFDS or Singapore's HSA. Eighteen counts those plus the two academic therapies authorised in Spain under the European Union's hospital exemption route, a pathway that lets a member state permit an unlicensed advanced therapy made in a hospital, for use in that hospital, without a central marketing authorisation. The exemption is not an approval in the sense the other seventeen are, which is why commercial tallies usually keep it out and broad surveys usually fold it in.

Then there is the detail that makes eighteen arguable rather than clean. Barcelona's ARI-0001, authorised in 2021, uses the same construct that was later licensed to an Indian manufacturer and approved there as Qartemi. If you count products by molecular identity rather than by approval event, ARI-0001 and Qartemi are one product appearing twice, and the total lands at eighteen rather than nineteen. If you count approval events, it is nineteen. Both numbers appear in print.

For a patient, none of this matters except as a warning: when someone quotes a global total at you — in a brochure, in a chat group, in a sales call — ask which country's approval sits behind it. The rest is trivia.

The Approval Map, Jurisdiction by Jurisdiction

Here is the landscape as it stands in the last quarter of 2026, grouped by regulator rather than by company, because the regulator is what determines whether a patient can be treated.

One line in that table deserves separating out, because it is the most common error in market coverage. The United States figure is often written as seven plus one plus one, and then reported as nine cell therapies or, worse, as nine CAR-T products. They are not interchangeable. The TIL product is a tumour-infiltrating lymphocyte therapy for advanced melanoma. The TCR-T product is a T-cell receptor therapy for synovial sarcoma. Both are engineered or expanded T-cell treatments for solid tumours, and both are genuine advances, but neither is a chimeric antigen receptor T cell. A patient with lymphoma cannot be switched onto either, and a brochure that lists them together is either careless or hoping you will not notice.

What the table does show clearly is a structural fact that rarely gets stated: China is the only country other than the United States where the portfolio is deep enough for second-line choices to exist. Everywhere else, approval means one product, one target, one indication, and a take-it-or-leave-it conversation.

What China's Nine Actually Add — and What They Do Not

The Chinese portfolio is usually presented as nine options. It is closer to two options and a half, and understanding why is more useful than the headline.

Of the nine, almost all target one of two markers: CD19, which sits on B-cell lymphomas and leukaemias, or BCMA, which sits on plasma cells and therefore on myeloma. One — the product approved in June 2026 — targets Claudin18.2 and is the first CAR-T anywhere approved for a solid tumour, in gastric and gastro-oesophageal junction adenocarcinoma. So the real menu is: B-cell disease, plasma-cell disease, and one narrow solid-tumour indication.

That concentration is not a weakness. It is the reason prices moved. Where several products share a target, they are therapeutically substitutable in a way that products across targets are not, and substitutability is what produces a price floor. The cheapest CD19 product in China now lists at about ¥899,000, having entered a market where the earliest entrants still charge ¥1.16 to 1.29 million. That gap did not come from a clinical breakthrough. It came from competition inside a single target class.

The second thing the nine add is molecular diversity that exists nowhere else. Most of the Chinese products are domestic molecules rather than in-licensed Western ones, which means their trial populations, their manufacturing processes and their safety databases are separate from the Western ones. For a Chinese patient that is straightforward. For an international patient it cuts both ways: there are real data behind each approval, and those data were generated in a population and a health system that may differ from yours.

See the full list of nine products with current list prices and payment routes.

Read how the Chinese approval sequence unfolded, product by product.

The Deal Map: Why the Money Predicts the Geography

Approvals tell you what exists today. Acquisitions tell you what will exist in three years, and in this field they tell you something more specific: which bottleneck the industry believes is the binding one.

Read the bottom four rows together and the pattern is not ambiguous. The buyers are not paying for another CD19 product; there are enough of those and the prices are converging. They are paying to escape the constraint that has defined the field since 2017: one batch, one patient, a cleanroom, a five-week wait, and a price that cannot fall below the cost of a bespoke manufacturing run.

In vivo engineering and allogeneic manufacturing attack that constraint from opposite ends. In vivo delivery skips the cleanroom entirely by instructing the patient's own cells inside their body. Allogeneic manufacturing makes one batch for many patients, turning a craft process into a pharmaceutical one. Either, if it works, changes the price structure rather than shaving a percentage off it.

The geography follows from that. A therapy that requires a five-week bespoke manufacturing slot can only be delivered in countries that already have cell-therapy infrastructure, which is why the approval map looks the way it does. A therapy that ships as a vial can be delivered anywhere there is a hospital, which is why the next version of this map will have more countries on it than the current one.

Three Technical Fronts Still Open

The industry's own summary of its problems is unusually candid, and it has not changed much in five years.

Gene transfer and cell modification

Getting the receptor into the T cell efficiently, and without the cell losing fitness in the process, remains the first engineering problem. CRISPR-based editing and electroporation are the two routes under most active development, and both trade one kind of risk for another.

Controllability and toxicity

A CAR-T cell is a living drug that cannot be stopped by discontinuing an infusion. Switch receptors and safety circuits — designs in which the cell's activity can be dialled down or turned off pharmacologically — are the response, and they matter most precisely in the solid-tumour setting, where the toxicity profile is harsher and the efficacy lower.

Finding targets that only tumours carry

This is the real bottleneck for solid tumours, and it is a biology problem rather than an engineering one. Hundreds of trials are running against solid tumours and most will fail, because the antigens being targeted are also present on normal tissue and the therapeutic window is thin. The one approval that exists works because Claudin18.2 is expressed densely enough in gastric tissue to hit, and the surrounding normal stomach can be lived with. That is a narrow window, and it does not generalise automatically to pancreas, lung or colon.

That last point is worth holding onto. The single solid-tumour approval is a genuine milestone and it is also, so far, a single data point. In the trial behind it, median progression-free survival was 3.25 months against 1.77 for physician's choice, with response rates of 22 and 4 percent. Real, measurable, and not a cure.

See which solid tumours have an approval and which remain trial-only.

The Off-the-Shelf Bet, and Why It Matters Most in Asia

Almost every product on the market, and the overwhelming majority of trials, use the patient's own cells. The next step — the one the acquisitions above are funding — is an allogeneic product made from a healthy donor's cells, available in advance, and infused without a manufacturing wait.

The commercial logic is strongest in exactly the markets where CAR-T is currently least accessible. A single batch serving many patients divides the manufacturing cost; a product that can be held in inventory removes the scheduling bottleneck that limits a centre to a handful of patients a month; and a product that does not require apheresis can be given in places without a cell-collection programme. In China, where nine products are approved and almost all of them are paid for out of pocket, that arithmetic is the difference between a therapy for thousands and a therapy for tens of thousands.

The biology is the obstacle. Allogeneic cells are recognised as foreign and cleared, so persistence is short; and they can attack the recipient, so graft-versus-host disease has to be engineered out with additional edits, each of which adds a failure mode. Nothing approved today is allogeneic, and the honest timeline for a first approval is years rather than quarters.

Which leads to the practical instruction. If you are eligible for an approved autologous product now, the existence of a better product in development is not a reason to wait. Advanced disease does not hold its position, and a bird-in-hand calculation in oncology almost always favours treating with what has been measured over waiting for what has been promised.

Autoimmune Disease: The Expansion Nobody Prices In

The other direction of travel is not toward a new manufacturing model but toward a new patient population. Several hundred active trials are now testing CAR-T in autoimmune disease — lupus, multiple sclerosis, systemic sclerosis and others — on the reasoning that the same cell that can eliminate a B-cell population in lymphoma can reset an immune system that is attacking its own tissue.

The early results have been striking enough to change the field's centre of gravity, and the mechanism is genuinely different from anything else in rheumatology: this is not suppression but depletion followed by reconstitution, an attempt at a reset rather than a brake.

Two cautions belong here, and they are the reason this section is short. First, almost none of it is approved. Patients are being treated within trials or, in some jurisdictions, outside them, and the difference between those two situations is the entire difference between evidence and anecdote. Second, the risk profile that is acceptable in a patient with refractory lymphoma may not be acceptable in a patient with lupus who has other options, because the toxicity of CAR-T is real and its long-term consequences are still being characterised.

If someone offers CAR-T for an autoimmune diagnosis, the first question is not which product but which approval or which registered trial. There is, at present, no approved CAR-T indication outside oncology in any of the six jurisdictions above.

A Multi-Billion-Dollar Industry, and the Gap It Leaves

The market has crossed from experimental to industrial. Revenue is now measured in billions of dollars a year, and the companies that dominate it have the balance sheets to match. That is genuinely good news for patients in the long run: industrial capital is what funds the next generation of manufacturing and the trials that will move CAR-T out of the last-line setting.

But it would be a mistake to read industry scale as access. The revenue is concentrated in one market, at one price point, for a patient population that is a small fraction of the diagnoses these products nominally address. In China the opposite pattern holds: nine approvals, a price band from roughly ¥899,000 to ¥1.29 million, no product inside the national reimbursement list, five inside a commercial innovative-drug scheme that took effect in January 2026, and a city-level supplemental insurance layer that covers a majority of the population but requires local enrolment.

That last clause is the one international readers need. Supplemental schemes and the national scheme are tied to residency and local insurance enrolment. A patient flying in for treatment does not qualify for either, which means the realistic quotation is the list price plus hospital service fees. That remains far below the US list price for equivalent therapy, and it is not the reimbursed number that Chinese patients sometimes quote in online forums.

Four Questions Worth Asking of Any Number in This Article

The map is useful only if it is read as a map and not as a brochure. Four questions do most of the work.

1. Approved where?
   A global total is marketing. The operative number is how many products hold approval in the country that will treat you, and whether the one you are being offered is among them. Seventeen worldwide and one at your hospital is a different conversation from seventeen and seventeen.
2. Which target?
   Ask for the antigen, not the brand. Two products sharing a target are plausibly alternatives to each other; two products on different targets are not, and a centre that cannot tell you the target cannot tell you whether you have a choice.
3. CAR-T, TIL, or TCR-T?
   They are different therapies with different indications, different manufacturing and different risk profiles, and the market coverage routinely blends them. If a claim rests on combining them, the claim is inflated.
4. Approval, exemption, trial, or none?
   These four statuses carry entirely different levels of scrutiny. A hospital-exemption product is legal in its own jurisdiction and has not been through a central review. A trial is not a treatment you can buy. Anything outside all four is not medicine yet, whatever it is called.

Seventeen approvals, nine of them Chinese, is a real milestone, and the industry is entitled to say so. What it does not tell you is whether the therapy is available where you live, affordable with your insurance, appropriate for your diagnosis, or safe in the hands of the centre that is offering it. Those are four separate questions, and the map answers none of them.

Send us the pathology report and we will tell you which approved product, if any, matches the diagnosis.

Source: industry round-up published 20 October 2026 drawing on national regulator approvals, company disclosures and clinical trial registries, with data current to August 2026; national product approvals and list prices verified against our own records current to 31 October 2026.

Send Us Your Pathology Report